<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165085</url>
  </required_header>
  <id_info>
    <org_study_id>P110907</org_study_id>
    <nct_id>NCT02165085</nct_id>
  </id_info>
  <brief_title>Biomarkers in Vascular Ehlers-Danlos Syndrome</brief_title>
  <acronym>MEDIC</acronym>
  <official_title>Identification of Plasmatic Biomarkers in Vascular Ehlers-Danlos Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether patients with vascular Ehlers-Danlos
      syndrome present significant and specific changes of arterial endothelial and smooth muscular
      cell signalling/secretion, in comparison to matched healthy volunteers and patients with
      spontaneous arterial dissections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascular Ehlers-Danlos syndrome is a rare inherited disease which confers exceptional organ
      fragility in seamingly healthy young adults. The disease is caused by a mutation in the
      COL3A1 gene encoding type III collagen, critical to ensure physical resistance to mechanical
      stress of hollow organs. The disease results in increased tissular fragility, responsible of
      spontaneous arterial ruptures and dissections and spontaneous bowel perforations. The
      life-expectancy of patients with vascular Ehlers-Danlos syndrome is reduced by these
      recurring accidents. The exact mechanisms that trigger arterial accidents are unknown. Recent
      findings suggest a possible deleterious effect of inflammation and a possible dysregulation
      of the TGF-beta pathway. Thus, the purpose of this study is to identify further alterations
      in vascular endothelial and smooth muscular cell signalling/secretion, and to confirm
      previously suggested mechanisms of arterial accidents in vEDS patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic value of plasma biomarkers SEDv</measure>
    <time_frame>At the end of study (2 years after period of inclusion for first patient)</time_frame>
    <description>Analysis of the diagnostic value of different levels of plasma concentrations of microRNAs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reference value of biomarkers</measure>
    <time_frame>At the end of study (2 years after period of inclusion for first patient)</time_frame>
    <description>Compare patients with controls SEDv and two populations (patients with arterial accident spontaneous and healthy volunteers):microRNAs, the expression of circulating markers of tissue remodeling (plasma procollagen type I and III), the expression of a marker of inflammation (sensitivity C-reactive protein CRPus)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">211</enrollment>
  <condition>Vascular Ehlers-Danlos Syndrome</condition>
  <arm_group>
    <arm_group_label>Vascular-Ehlers Danlos syndrome</arm_group_label>
    <description>N=50 patients with vascular Ehlers-Danlos syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spontaneous arterial dissection(s)</arm_group_label>
    <description>N=50 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>n=100 Healthy volunteers</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with vascular Ehlers-Danlos syndrome and patients with spontaneous dissection(s)
        will be recruited from the French National Referral Centre for Rare arterial diseases,
        Hopital Europeen Georges Pompidou, Paris, France. Healthy volunteers will be recruited by
        the clinical investigations center, Hopital Europeen Georges Pompidou, Paris, France
        (random community sample).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with vascular Ehlers-Danlos syndrome must have been positively tested for a
             pathogenic mutation within the COL3A1 gene.

          -  In patients with arterial dissection(s) any associated systemic arterial disease must
             have been ruled out, especially vascular Ehers-Danlos syndrome

        Exclusion Criteria:

        -All subjects must not present any chronic systemic disease, any acute disease within seven
        days prior to enrollment, diabetes mellitus and arterial hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Frank, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Reference des Maladies Vasculaires Rares, Hopital Europeen Georges Pompidou, APHP, Paris France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.maladiesvasculairesrares.com</url>
    <description>Click here for more information about this disease Vascular Ehlers-Danlos Syndrome</description>
  </link>
  <reference>
    <citation>Morissette R, Schoenhoff F, Xu Z, Shilane DA, Griswold BF, Chen W, Yang J, Zhu J, Fert-Bober J, Sloper L, Lehman J, Commins N, Van Eyk JE, McDonnell NB. Transforming growth factor-β and inflammation in vascular (type IV) Ehlers-Danlos syndrome. Circ Cardiovasc Genet. 2014 Feb;7(1):80-8. doi: 10.1161/CIRCGENETICS.113.000280. Epub 2014 Jan 6.</citation>
    <PMID>24399159</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Ehlers-Danlos syndrome, vascular type</keyword>
  <keyword>Pathophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

